Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.
Identifieur interne : 002E57 ( PubMed/Curation ); précédent : 002E56; suivant : 002E58Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.
Auteurs : David Langleben [Canada] ; Nazzareno Galiè [Italie] ; Jianguo He [République populaire de Chine] ; Yigao Huang [République populaire de Chine] ; Marc Humbert [France] ; Anne Keogh [Australie] ; Lewis J. Rubin [États-Unis] ; Daxin Zhou [République populaire de Chine] ; John Curram [Royaume-Uni] ; Neil Davie [Allemagne] ; Hossein-Ardeschir Ghofrani [Royaume-Uni]Source :
- The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation [ 1557-3117 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Femelle, Fonction ventriculaire droite (), Fonction ventriculaire droite (physiologie), Humains, Hypertension pulmonaire (physiopathologie), Hypertension pulmonaire (traitement médicamenteux), Marche à pied (physiologie), Mâle, Méthode en double aveugle, Pression ventriculaire (), Pyrazoles (administration et posologie), Pyrimidines (administration et posologie), Relation dose-effet des médicaments, Résultat thérapeutique, Épreuve d'effort (), Études de suivi.
- MESH :
- administration et posologie : Pyrazoles, Pyrimidines.
- physiologie : Fonction ventriculaire droite, Marche à pied.
- physiopathologie : Hypertension pulmonaire.
- traitement médicamenteux : Hypertension pulmonaire.
- Adulte d'âge moyen, Femelle, Fonction ventriculaire droite, Humains, Mâle, Méthode en double aveugle, Pression ventriculaire, Relation dose-effet des médicaments, Résultat thérapeutique, Épreuve d'effort, Études de suivi.
English descriptors
- KwdEn :
- Dose-Response Relationship, Drug, Double-Blind Method, Exercise Test (drug effects), Female, Follow-Up Studies, Humans, Hypertension, Pulmonary (drug therapy), Hypertension, Pulmonary (physiopathology), Male, Middle Aged, Pyrazoles (administration & dosage), Pyrimidines (administration & dosage), Treatment Outcome, Ventricular Function, Right (drug effects), Ventricular Function, Right (physiology), Ventricular Pressure (drug effects), Walking (physiology).
- MESH :
- chemical , administration & dosage : Pyrazoles, Pyrimidines.
- drug effects : Exercise Test, Ventricular Function, Right, Ventricular Pressure.
- drug therapy : Hypertension, Pulmonary.
- physiology : Ventricular Function, Right, Walking.
- physiopathology : Hypertension, Pulmonary.
- Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
In PATENT-1, riociguat significantly improved 6-minute walking distance (6MWD) and a range of secondary end-points in patients with pulmonary arterial hypertension (PAH). We investigated whether riociguat increased the proportion of patients achieving clinically relevant responder thresholds compared with placebo during PATENT-1.
DOI: 10.1016/j.healun.2014.12.001
PubMed: 25703961
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F35
Links to Exploration step
pubmed:25703961Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.</title><author><name sortKey="Langleben, David" sort="Langleben, David" uniqKey="Langleben D" first="David" last="Langleben">David Langleben</name><affiliation wicri:level="1"><nlm:affiliation>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Canada. Electronic address: david.langleben@mcgill.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal</wicri:regionArea></affiliation></author><author><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galiè">Nazzareno Galiè</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Hospital, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Hospital, Bologna</wicri:regionArea></affiliation></author><author><name sortKey="He, Jianguo" sort="He, Jianguo" uniqKey="He J" first="Jianguo" last="He">Jianguo He</name><affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Huang, Yigao" sort="Huang, Yigao" uniqKey="Huang Y" first="Yigao" last="Huang">Yigao Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou, Guangdong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Cardiology, Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou, Guangdong</wicri:regionArea></affiliation></author><author><name sortKey="Humbert, Marc" sort="Humbert, Marc" uniqKey="Humbert M" first="Marc" last="Humbert">Marc Humbert</name><affiliation wicri:level="1"><nlm:affiliation>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin-Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin-Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Keogh, Anne" sort="Keogh, Anne" uniqKey="Keogh A" first="Anne" last="Keogh">Anne Keogh</name><affiliation wicri:level="1"><nlm:affiliation>St Vincent's Hospital, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St Vincent's Hospital, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Rubin, Lewis J" sort="Rubin, Lewis J" uniqKey="Rubin L" first="Lewis J" last="Rubin">Lewis J. Rubin</name><affiliation wicri:level="2"><nlm:affiliation>University of California, San Diego, La Jolla, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>University of California, San Diego, La Jolla</wicri:cityArea></affiliation></author><author><name sortKey="Zhou, Daxin" sort="Zhou, Daxin" uniqKey="Zhou D" first="Daxin" last="Zhou">Daxin Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Curram, John" sort="Curram, John" uniqKey="Curram J" first="John" last="Curram">John Curram</name><affiliation wicri:level="1"><nlm:affiliation>Global Development, Bayer Pharma AG, Newbury, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Global Development, Bayer Pharma AG, Newbury</wicri:regionArea></affiliation></author><author><name sortKey="Davie, Neil" sort="Davie, Neil" uniqKey="Davie N" first="Neil" last="Davie">Neil Davie</name><affiliation wicri:level="1"><nlm:affiliation>Global Clinical Development, Bayer Pharma AG, Wuppertal, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Global Clinical Development, Bayer Pharma AG, Wuppertal</wicri:regionArea></affiliation></author><author><name sortKey="Ghofrani, Hossein Ardeschir" sort="Ghofrani, Hossein Ardeschir" uniqKey="Ghofrani H" first="Hossein-Ardeschir" last="Ghofrani">Hossein-Ardeschir Ghofrani</name><affiliation wicri:level="1"><nlm:affiliation>University of Giessen and Marburg Lung Center, Giessen, Germany, German Center of Lung Research, and Department of Medicine, Imperial College London, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Giessen and Marburg Lung Center, Giessen, Germany, German Center of Lung Research, and Department of Medicine, Imperial College London, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25703961</idno><idno type="pmid">25703961</idno><idno type="doi">10.1016/j.healun.2014.12.001</idno><idno type="wicri:Area/PubMed/Corpus">002F35</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002F35</idno><idno type="wicri:Area/PubMed/Curation">002E57</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002E57</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.</title><author><name sortKey="Langleben, David" sort="Langleben, David" uniqKey="Langleben D" first="David" last="Langleben">David Langleben</name><affiliation wicri:level="1"><nlm:affiliation>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Canada. Electronic address: david.langleben@mcgill.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal</wicri:regionArea></affiliation></author><author><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galiè">Nazzareno Galiè</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Hospital, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Hospital, Bologna</wicri:regionArea></affiliation></author><author><name sortKey="He, Jianguo" sort="He, Jianguo" uniqKey="He J" first="Jianguo" last="He">Jianguo He</name><affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Huang, Yigao" sort="Huang, Yigao" uniqKey="Huang Y" first="Yigao" last="Huang">Yigao Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou, Guangdong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Cardiology, Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou, Guangdong</wicri:regionArea></affiliation></author><author><name sortKey="Humbert, Marc" sort="Humbert, Marc" uniqKey="Humbert M" first="Marc" last="Humbert">Marc Humbert</name><affiliation wicri:level="1"><nlm:affiliation>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin-Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin-Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Keogh, Anne" sort="Keogh, Anne" uniqKey="Keogh A" first="Anne" last="Keogh">Anne Keogh</name><affiliation wicri:level="1"><nlm:affiliation>St Vincent's Hospital, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St Vincent's Hospital, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Rubin, Lewis J" sort="Rubin, Lewis J" uniqKey="Rubin L" first="Lewis J" last="Rubin">Lewis J. Rubin</name><affiliation wicri:level="2"><nlm:affiliation>University of California, San Diego, La Jolla, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>University of California, San Diego, La Jolla</wicri:cityArea></affiliation></author><author><name sortKey="Zhou, Daxin" sort="Zhou, Daxin" uniqKey="Zhou D" first="Daxin" last="Zhou">Daxin Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Curram, John" sort="Curram, John" uniqKey="Curram J" first="John" last="Curram">John Curram</name><affiliation wicri:level="1"><nlm:affiliation>Global Development, Bayer Pharma AG, Newbury, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Global Development, Bayer Pharma AG, Newbury</wicri:regionArea></affiliation></author><author><name sortKey="Davie, Neil" sort="Davie, Neil" uniqKey="Davie N" first="Neil" last="Davie">Neil Davie</name><affiliation wicri:level="1"><nlm:affiliation>Global Clinical Development, Bayer Pharma AG, Wuppertal, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Global Clinical Development, Bayer Pharma AG, Wuppertal</wicri:regionArea></affiliation></author><author><name sortKey="Ghofrani, Hossein Ardeschir" sort="Ghofrani, Hossein Ardeschir" uniqKey="Ghofrani H" first="Hossein-Ardeschir" last="Ghofrani">Hossein-Ardeschir Ghofrani</name><affiliation wicri:level="1"><nlm:affiliation>University of Giessen and Marburg Lung Center, Giessen, Germany, German Center of Lung Research, and Department of Medicine, Imperial College London, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Giessen and Marburg Lung Center, Giessen, Germany, German Center of Lung Research, and Department of Medicine, Imperial College London, London</wicri:regionArea></affiliation></author></analytic><series><title level="j">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</title><idno type="eISSN">1557-3117</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Exercise Test (drug effects)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Hypertension, Pulmonary (drug therapy)</term><term>Hypertension, Pulmonary (physiopathology)</term><term>Male</term><term>Middle Aged</term><term>Pyrazoles (administration & dosage)</term><term>Pyrimidines (administration & dosage)</term><term>Treatment Outcome</term><term>Ventricular Function, Right (drug effects)</term><term>Ventricular Function, Right (physiology)</term><term>Ventricular Pressure (drug effects)</term><term>Walking (physiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Fonction ventriculaire droite ()</term><term>Fonction ventriculaire droite (physiologie)</term><term>Humains</term><term>Hypertension pulmonaire (physiopathologie)</term><term>Hypertension pulmonaire (traitement médicamenteux)</term><term>Marche à pied (physiologie)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Pression ventriculaire ()</term><term>Pyrazoles (administration et posologie)</term><term>Pyrimidines (administration et posologie)</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Épreuve d'effort ()</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Pyrazoles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Pyrazoles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Exercise Test</term><term>Ventricular Function, Right</term><term>Ventricular Pressure</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertension, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Fonction ventriculaire droite</term><term>Marche à pied</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Ventricular Function, Right</term><term>Walking</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Hypertension pulmonaire</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hypertension, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hypertension pulmonaire</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Fonction ventriculaire droite</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Pression ventriculaire</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Épreuve d'effort</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In PATENT-1, riociguat significantly improved 6-minute walking distance (6MWD) and a range of secondary end-points in patients with pulmonary arterial hypertension (PAH). We investigated whether riociguat increased the proportion of patients achieving clinically relevant responder thresholds compared with placebo during PATENT-1.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25703961</PMID><DateCreated><Year>2015</Year><Month>03</Month><Day>27</Day></DateCreated><DateCompleted><Year>2015</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-3117</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</Title><ISOAbbreviation>J. Heart Lung Transplant.</ISOAbbreviation></Journal><ArticleTitle>Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.</ArticleTitle><Pagination><MedlinePgn>338-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.healun.2014.12.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1053-2498(14)01496-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In PATENT-1, riociguat significantly improved 6-minute walking distance (6MWD) and a range of secondary end-points in patients with pulmonary arterial hypertension (PAH). We investigated whether riociguat increased the proportion of patients achieving clinically relevant responder thresholds compared with placebo during PATENT-1.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In PATENT-1, a randomized, double-blind study, treatment-naïve patients or patients on background PAH-targeted therapy with symptomatic PAH received 12 weeks of treatment with placebo, riociguat up to 2.5 mg 3 times daily, or riociguat up to 1.5 mg 3 times daily. Increases in 6MWD ≥40 m, 6MWD ≥380 m, cardiac index ≥2.5 liter/min/m(2), mixed venous oxygen saturation ≥65%, World Health Organization functional class I/II, N-terminal pro-brain natriuretic peptide <1,800 pg/ml, and right atrial pressure <8 mm Hg were chosen as threshold criteria of a positive response.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Riociguat increased the proportion of treatment-naïve patients and patients on background PAH-targeted therapy with 6MWD ≥380 m at Week 12 (+21% and +15%, respectively), whereas there was a small reduction in 6MWD in placebo-treated patients for both sub-groups. Riociguat also increased the proportion of treatment-naïve patients and patients on background PAH-targeted therapy achieving World Health Organization functional class I/II (+12% and +19%, respectively) and cardiac index ≥2.5 liter/min/m(2) (+30% and +33%, respectively) at Week 12, whereas there was little change in the respective placebo groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared with placebo, riociguat increased the proportion of treatment-naïve patients and patients on background PAH-targeted therapy who fulfilled criteria defining a positive response to therapy.</AbstractText><CopyrightInformation>Copyright © 2015 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Langleben</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Canada. Electronic address: david.langleben@mcgill.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galiè</LastName><ForeName>Nazzareno</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Hospital, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jianguo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yigao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humbert</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin-Bicêtre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keogh</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>St Vincent's Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubin</LastName><ForeName>Lewis J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>University of California, San Diego, La Jolla, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Daxin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curram</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Global Development, Bayer Pharma AG, Newbury, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davie</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Global Clinical Development, Bayer Pharma AG, Wuppertal, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghofrani</LastName><ForeName>Hossein-Ardeschir</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>University of Giessen and Marburg Lung Center, Giessen, Germany, German Center of Lung Research, and Department of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Heart Lung Transplant</MedlineTA><NlmUniqueID>9102703</NlmUniqueID><ISSNLinking>1053-2498</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>625115-55-1</RegistryNumber><NameOfSubstance UI="C542595">riociguat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005080" MajorTopicYN="N">Exercise Test</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016278" MajorTopicYN="N">Ventricular Function, Right</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017725" MajorTopicYN="N">Ventricular Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016138" MajorTopicYN="N">Walking</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">pulmonary arterial hypertension</Keyword><Keyword MajorTopicYN="N">responder threshold criteria</Keyword><Keyword MajorTopicYN="N">riociguat</Keyword><Keyword MajorTopicYN="N">soluble guanylate cyclase stimulator</Keyword><Keyword MajorTopicYN="N">treatment response</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25703961</ArticleId><ArticleId IdType="pii">S1053-2498(14)01496-X</ArticleId><ArticleId IdType="doi">10.1016/j.healun.2014.12.001</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E57 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002E57 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25703961
|texte= Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25703961" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |